$0.00
(Market cap
$12 Mln
Revenue (TTM)
$133 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-252 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
144,955,008
10 Years Aggregate
CFO
$-2,173.19 Mln
EBITDA
$-2,676.93 Mln
Net Profit
$-2,769.11 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
| 76.5 | -38.5 | -73.4 | -94.6 | -79.6 | -72.1 | -41.1 |
|
BSE Sensex*
| -11.2 | -4.2 | -9.2 | -7.4 | 6.8 | 8.7 | 11.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
| -98.1 | -43.5 | -54.0 | -42.0 | -73.4 | 53.1 | 26.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Clovis Oncology (CLVS)
|
0.1 | 11.8 | 133.0 | -251.9 | -163.0 | -- | -- | 0.0 |
| 74.8 | 10,307.9 | 622.0 | -300.9 | -30.1 | -62 | -- | 17.6 | |
| 78.2 | 10,379.7 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 49.4 | 12,233.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.1 | 6.5 | |
| 119.4 | 13,020.0 | 1,080.2 | -433.2 | -39.8 | -- | -- | 60.9 | |
| 7.5 | 8,127.5 | 141.0 | -854.5 | -147.4 | -- | -- | 0.0 | |
| 300.0 | 8,785.0 | 417.3 | 225.0 | 42.8 | 18.6 | 39.9 | 6.8 | |
| 507.6 | 11,800.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.7 | |
| 422.3 | 11,992.5 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.4 | 20.0 | |
| 342.0 | 8,938.2 | 0.0 | -326.5 | -- | -37.2 | -- | 6.3 |
Shareholding Pattern
View DetailsAbout Clovis Oncology (CLVS)
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small... molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Co-Founder, CEO, Pres & Exec. Director
Mr. Patrick J. Mahaffy MA
-
Co-Founder, CEO, Pres & Exec. Director
Mr. Patrick J. Mahaffy MA
-
Headquarters
Boulder, CO
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Clovis Oncology (CLVS)
What is the current share price of Clovis Oncology Inc (CLVS) Today?
The share price of Clovis Oncology Inc (CLVS) is $0.09 (NASDAQ) as of 22-Feb-2023 09:30 EDT. Clovis Oncology Inc (CLVS) has given a return of -79.63% in the last 3 years.
What is the current PB & PE ratio of Clovis Oncology Inc (CLVS)?
Since, TTM earnings of Clovis Oncology Inc (CLVS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of Clovis Oncology Inc (CLVS)?
The 52-week high and low of Clovis Oncology Inc (CLVS) are Rs -- and Rs -- as of 21-May-2026.
What is the market cap of Clovis Oncology Inc (CLVS)?
Clovis Oncology Inc (CLVS) has a market capitalisation of $ 12 Mln as on 22-Feb-2023. As per SEBI classification, it is a company.
Should I invest in Clovis Oncology Inc (CLVS)?
Before investing in Clovis Oncology Inc (CLVS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.